Upgrade to SI Premium - Free Trial

Goldman Sachs Upgrades Biogen (BIIB) to Buy

July 26, 2017 5:07 AM
Goldman Sachs upgraded Biogen (NASDAQ: BIIB) from Neutral to Buy with a price target of $338.00 (from $228.00).Analyst Dr. Terrance ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change Hot Upgrades Upgrades

Next Articles